cLFM-Qol: A specific quality of life measurement tool for children from 11 to 15 years with low-flow malformations.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
18
10
2022
accepted:
08
03
2023
medline:
14
6
2023
pubmed:
28
3
2023
entrez:
27
3
2023
Statut:
ppublish
Résumé
Low-flow malformations (LFMs) are rare diseases with a significant impact on health-related quality of life (HRQoL), especially in children. No disease-specific questionnaire is available for children with LFMs. To develop and validate a specific HRQoL questionnaire for children from 11 to 15 years old suffering from LFMs. A preliminary questionnaire based on a verbatim from focus groups was created and sent to children from 11 to 15 years old suffering from LFMs, together with a dermatology-specific and a generic HRQoL questionnaire (cDLQI and EQ-5D-Y). A total of 75 from 201 included children responded to the questionnaires. The final version of the questionnaire (cLFM-QoL) included 15 questions and was not divisible into subscales. It demonstrated excellent internal consistency (cronbach 0.89), convergent validity and readability (SMOG 6.04). cLFM-QoL mean score (± SD) was 12.9/45 (8.03) for all grades of severity, for mild 8.22/45 (7.5), moderate 14.03/45 (8.35), severe 12.35/45 (6.59) or very severe patients 20.7/45 (3.39) (p 0.006). cLFM-QoL is a validated short and easy to use specific questionnaire with excellent psychometric capacities. It will be suitable for any children aged 11-15 with LFMs, in daily practice or clinical trials.
Sections du résumé
BACKGROUND
BACKGROUND
Low-flow malformations (LFMs) are rare diseases with a significant impact on health-related quality of life (HRQoL), especially in children. No disease-specific questionnaire is available for children with LFMs.
OBJECTIVE
OBJECTIVE
To develop and validate a specific HRQoL questionnaire for children from 11 to 15 years old suffering from LFMs.
METHODS
METHODS
A preliminary questionnaire based on a verbatim from focus groups was created and sent to children from 11 to 15 years old suffering from LFMs, together with a dermatology-specific and a generic HRQoL questionnaire (cDLQI and EQ-5D-Y).
RESULTS
RESULTS
A total of 75 from 201 included children responded to the questionnaires. The final version of the questionnaire (cLFM-QoL) included 15 questions and was not divisible into subscales. It demonstrated excellent internal consistency (cronbach 0.89), convergent validity and readability (SMOG 6.04). cLFM-QoL mean score (± SD) was 12.9/45 (8.03) for all grades of severity, for mild 8.22/45 (7.5), moderate 14.03/45 (8.35), severe 12.35/45 (6.59) or very severe patients 20.7/45 (3.39) (p 0.006).
CONCLUSION
CONCLUSIONS
cLFM-QoL is a validated short and easy to use specific questionnaire with excellent psychometric capacities. It will be suitable for any children aged 11-15 with LFMs, in daily practice or clinical trials.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1435-1442Informations de copyright
© 2023 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Références
Wassef M, Blei F, Adams D, Alomari A, Baselga E, Berenstein A, et al. Vascular anomalies classification: recommendations from the international society for the study of vascular anomalies. Paediatrics. 2015;136:e203-14.
Michelini S, Paolacci S, Manara E, Eretta C, Mattassi R, Lee BB, et al. Genetic tests in lymphatic vascular malformations and lymphedema. J Med Genet. 2018;55:222-32.
Brouillard P, Vikkula M. Genetic causes of vascular malformations. Hum Mol Genet. 2007;16:R140-9.
Mazereeuw-Hautier J, Syed S, Leisner RI, Harper JI. Extensive venous/lymphatic malformations causing life-threatening haematological complications. Br J Dermatol. 2007;157:558-63.
What quality of life? The WHOQOL Group. World health organization quality of life assessment. World Health Forum. 1996;17:354-6.
Guyatt GH, Ferrans CE, Halyard MY, Revicki DA, Symonds TL, Varricchio CG, et al. Exploration of the value of health-related quality-of-life information from clinical research and into clinical practice. Mayo Clin Proc. 2007;82:1229-39.
Weinstein JM, Chamlin SL. Quality of life in vascular anomalies. Lymphat Res Biol. 2005;3:256-9.
Fahrni JO, Cho EYN, Engelberger RP, Baumgartner I, von Känel R. Quality of life in patients with congenital vascular malformations. J Vasc Surg Venous Lymphat Disord. 2014;2:46-51.
Harvey JA, Nguyen H, Anderson KR, Schoch JJ, Bendel EC, Driscoll DJ, et al. Pain, psychiatric comorbidities, and psychosocial stressors associated with Klippel-Trenaunay syndrome. J Am Acad Dermatol. 2018;79:899-903.
Berger S, Andersen R, Dorenberg E, Meyer T, Weiss I, Smaastuen MC, et al. Quality of life in patients with vascular malformations outside the central nervous system: comparison with the general Norwegian population. J Plast Reconstr Aesthet Surg. 2019;72:1880-6.
Nguyen HL, Bonadurer GF III, Tollefson MM. Vascular malformations and health-related quality of life: a systematic review and meta-analysis. JAMA Dermatol. 2018;154:661-9.
Sheikh F, Akinkuotu A, Olutoye OO, Pimpalwar S, Cassady CI, Fernandes CJ, et al. Prenatally diagnosed neck masses: long-term outcomes and quality of life. J Pediatr Surg. 2015;50:1210-3.
Ramien ML, Ondrejchak S, Gendron R, Hatami A, McCuaig CC, Powell J, et al. Quality of life in paediatric patients before and after cosmetic camouflage of visible skin conditions. J Am Acad Dermatol. 2014;71:935-40.
Varni JW, Limbers CA, Burwinkle TM. Impaired health-related quality of life in children and adolescents with chronic conditions: a comparative analysis of 10 disease clusters and 33 disease categories/severities utilizing the PedsQL™ 4.0 Generic Core Scales. Health Qual Life Outcomes. 2007;5:43.
Wohlgemuth WA, Müller-Wille R, Teusch V, Hammer S, Wildgruber M, Uller W. Ethanolgel sclerotherapy of venous malformations improves health-related quality-of-life in adults and children - results of a prospective study. Eur Radiol. 2017;27:2482-8.
Casassa E, Bergeron A, Maruani A, Labreze C, Barbarot S, Aubert H, et al. Factors influencing quality of life in children with low-flow vascular malformations: a qualitative study using focus groups. J Eur Acad Dermatol Venereol. 2021;35:755-61.
Rumsey N. Psychosocial adjustment to skin conditions resulting in visible difference (disfigurement): What do we know? Why do not we know more? How shall we move forward? Int J Womens Dermatol. 2018;4:2-7.
Chernyshov P, de Korte J, Tomas-Aragones L, Lewis-Jones S, Force the EQ of LT. EADV Taskforce's recommendations on measurement of health-related quality of life in paediatric dermatology. J Eur Acad Dermatol Venereol. 2015;29:2306-16.
Chernyshov PV. Dermatological quality of life instruments in children. G Ital Dermatol E Venereol Organo Uff Soc Ital Dermatol E Sifilogr. 2013;148:277-85.
Jandhyala R. Neutral theory: applicability and neutrality of using generic health-related quality of life tools in diseases or conditions where specific tools are available. BMC Med Res Methodol. 2021;21:86.
Eiser C, Morse R. Quality-of-life measures in chronic diseases of childhood. Health Technol Assess (Winch Eng). 2001;5:1-157.
Eiser C, Morse R. Can parents rate their child's health-related quality of life? Results of a systematic review. Qual Life Res Int J Qual Life Asp Treat Care Rehab. 2001;10:347-57.
Lewis-Jones MS, Finlay AY, Dykes PJ. The infants' dermatitis quality of life index. Br J Dermatol. 2001;144:104-10.
Chamlin SL, Cella D, Frieden IJ, Williams ML, Mancini AJ, Lai JS, et al. Development of the childhood atopic dermatitis impact scale: initial validation of a quality-of-life measure for young children with atopic dermatitis and their families. J Invest Dermatol. 2005;125:1106-11.
Baars RM, Atherton CI, Koopman HM, Bullinger M, Power M. The European DISABKIDS project: development of seven condition-specific modules to measure health related quality of life in children and adolescents. Health Qual Life Outcomes. 2005;3:1-9.
Motley R j, Finlay AY. Practical use of a disability index in the routine management of acne. Clin Exp Dermatol. 1992;17:1-3.
Dreno B, Finlay AY, Nocera T, Verrière F, Taïeb C, Myon E. The cardiff acne disability index: cultural and linguistic validation in French. Dermatology. 2004;208:104-8.
Rapp SR, Feldman SR, Graham G, Fleischer AB, Brenes G, Dailey M. The acne quality of life index (Acne-QOLI). Am J Clin Dermatol. 2006;7:185-92.
Oostveen A, Jong E, Evers A, Donders A, Kerkhof P, Seyger M. Reliability, responsiveness and validity of scalpdex in children with scalp psoriasis: the dutch study. Acta Derm Venereol. 2014;94:198-202.
Hoornweg MJ, Grootenhuis MA, van der Horst CMAM. Health-related quality of life and impact of haemangiomas on children and their parents. J Plast Reconstr Aesthet Surg. 2009;62:1265-71.
Terwee CB, Prinsen CAC, Chiarotto A, Westerman MJ, Patrick DL, Alonso J, et al. COSMIN methodology for evaluating the content validity of patient-reported outcome measures: a Delphi study. Qual Life Res. 2018;27:1159-70.
Salek M s, Jung S, Brincat-Ruffini LA, Macfarlane L, Lewis-Jones MS, Basra MKA, et al. Clinical experience and psychometric properties of the Children's Dermatology Life Quality Index (CDLQI), 1995-2012. Br J Dermatol. 2013;169:734-59.
Olsen JR, Gallacher J, Finlay AY, Piguet V, Francis NA. Quality of life impact of childhood skin conditions measured using the Children's Dermatology Life Quality Index (CDLQI): a meta-analysis. Br J Dermatol. 2016;174:853-61.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210-6.
Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol. 1995;132:942-9.
Holme S a, Man I, Sharpe JI, Dykes PJ, Lewis-Jones MS, Finlay AY. The Children's dermatology life quality index: validation of the cartoon version. Br J Dermatol. 2003;148:285-90.
Ramos-Goñi JM, Estévez-Carrillo A, Rivero-Arias O, Rowen D, Mott D, Shah K, et al. Does changing the age of a child to be considered in 3-level version of EQ-5D-Y discrete choice experiment-based valuation studies affect health preferences? Value Health. 2022;25:1196-204.
Ravens-Sieberer U, Wille N, Badia X, Bonsel G, Burström K, Cavrini G, et al. Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study. Qual Life Res. 2010;19:887-97.
Kreimeier S, Greiner W. EQ-5D-Y as a health-related quality of life instrument for children and adolescents: the instrument's characteristics, development, current use, and challenges of developing its value set. Value Health. 2019;22:31-7.
Kreimeier S, Oppe M, Ramos-Goñi JM, Cole A, Devlin N, Herdman M, et al. Valuation of EuroQol five-dimensional questionnaire, youth version (EQ-5D-Y) and EuroQol five-dimensional questionnaire, three-level version (EQ-5D-3L) Health States: the Impact of Wording and Perspective. Value Health. 2018;21:1291-8.
Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16:297-334.
McDonald R. Test Theory: A Unified Treatment [Internet]. New York: Psychology Press; 2013. https://doi.org/10.4324/9781410601087
Trizano-Hermosilla I, Alvarado JM. Best Alternatives to Cronbach's alpha reliability in realistic conditions: congeneric and asymmetrical measurements. Front Psychol. 2016;7:769. https://doi.org/10.3389/fpsyg.2016.00769
Hu L, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. Struct Equ Model Multidiscip J. 1999;6:1-55.
Shi D, Lee T, Maydeu-Olivares A. Understanding the model size effect on SEM fit indices. Educ Psychol Meas. 2019;79:310-34.
Contreras A, García-Alonso R, Echenique M, Daye-Contreras F. The SOL formulas for converting SMOG readability scores between health education materials written in Spanish, English, and French. J Health Commun. 1999;4:21-9.
Akoglu H. User's guide to correlation coefficients. Turk J Emerg Med. 2018;18:91-3.
Koo TK, Li MY. A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. J Chiropr Med. 2016;15:155-63.
Sedaghat AR. Understanding the Minimal Clinically Important Difference (MCID) of Patient-Reported Outcome Measures. Otolaryngol--Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg. 2019;161:551-60.
Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, et al. Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2005;8:94-104.
Chen P, Lin KC, Liing RJ, Wu CY, Chen CL, Chang KC. Validity, responsiveness, and minimal clinically important difference of EQ-5D-5L in stroke patients undergoing rehabilitation. Qual Life Res. 2016;25:1585-96.
Maruani A, Boccara O, Bessis D, Guibaud L, Vabres P, Mazereeuw-Hautier J, et al. Treatment of voluminous and complicated superficial slow-flow vascular malformations with sirolimus (PERFORMUS): protocol for a multicenter phase 2 trial with a randomized observational-phase design. Trials. 2018;19:1-9.
Leducq S, Caille A, Barbarot S, Bénéton N, Bessis D, Boccara O, et al. Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial. Trials. 2019;20:1-11.
Venot Q, Blanc T, Rabia SH, Berteloot L, Ladraa S, Duong JP, et al. Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature. 2018;558:540-6.